

Product datasheet for **TP721381M**

CLDN18.2 Human Recombinant Protein, Virus-like Particle

Product data:

Product Type:	Recombinant Proteins
Description:	Recombinant Human CLDN18.2 full length protein-Virus-like particle, 100µg
Species:	Human
Expression Host:	HEK293
Expression cDNA Clone or AA Sequence:	C-terminal Flag tagged overexpression cDNA clone
Tag:	C-term Flag Tag
Predicted MW:	The Human CLDN18.2 Protein has a predicted MW of 29 kDa. Due to PTM, the actual MW on SDS-PAGE gel is around 50kDa.
Concentration:	Please refer to the Certificate of Analysis (COA) for the lot-specific concentration before lyophilization.
Buffer:	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization.
Reconstitution Method:	<ol style="list-style-type: none"> 1. Before opening the tube cap, centrifuge the sample tube at 5000g for 3-5min at room temperature to ensure the lyophilized sample settles down at the bottom of the tube. 2. Calculate the volume for reconstitution (in µL) using the formula: [Quantity (mg)/Concentration (mg/mL)]x1000 3. Dissolve the lyophilized protein sample in sterile water based on the calculated volume (µL) 4. After adding sterile water, cover the lid and mix by gently tapping the tube 5-10 times. Note: Do not vortex or vigorously pipette the sample.
Storage:	Store at -20°C to -80°C for 12 months in lyophilized form.
Stability:	After reconstitution, if not intended for use within a month, aliquot and store at -80°C . Avoid repeated freezing and thawing.
Locus ID:	51208
UniProt ID:	P56856
Synonyms:	Claudin 18.2
Protein Families:	Transmembrane
Protein Pathways:	Cell adhesion molecules (CAMs), Leukocyte transendothelial migration, Tight junction



[View online »](#)

Product images:




Figure 2. FACS analysis of CLDN18.2 VLP. A. Negative Control 1: CLDN18.2 VLP were stained only with Goat anti-human IgG Fc-PE secondary antibody. B. Negative Control 2: Control VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar) at 1µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody. C. Negative Control 3: CLDN18.2 VLP were stained with anti-BCMA antibody (an irrelevant antibody) at 1µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody. D. CLDN18.2 VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar) at 1µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.

ELISA assay to evaluate CLDN18.2 VLP

0.5µg Human CLDN18.2 VLP per well




Figure 1. ELISA plates were pre-coated with 0.5µg/per well purified human CLDN18.2 VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (Zolbetuximab biosimilar; IMAB362) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for IMAB362 binding with CLDN18.2 VLP is 15.37ng/ml.